Myriad Genetics Names George Daneker Jr., MD, as President and Chief Clinical Officer of Oncology
January 30 2024 - 5:00PM
Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing
and precision medicine, today announced the appointment of George
Daneker Jr., MD, as President and Chief Clinical Officer of
Oncology, effective March 18, 2024.
Dr. Daneker brings more than 30 years of oncology and precision
medicine experience deeply rooted in providing accessible and
equitable oncology care for all patients. In his new role, he will
be responsible for leading the commercial and clinical strategy to
advance Myriad’s oncology portfolio, which currently offers
germline testing, tumor profiling and companion diagnostic options,
including homologous recombination deficiency (HRD) testing.
“We are pleased to welcome George to Myriad. He is an
accomplished healthcare leader with a proven ability to spearhead
and manage the development of precision medicine and clinical
research programs in the oncology space,” said Paul J. Diaz,
president and CEO, Myriad Genetics. “His strategic vision and
combined clinical, research and academic experience will be
instrumental in leading the continued innovation, growth and
development of our oncology portfolio, including our planned
product expansions into liquid biopsy and minimal residual disease
(MRD) testing.”
Dr. Daneker most recently served as the System Vice President
for Oncology and Medical Director of the Oncology Clinical Program
at SSM Health, a not-for-profit health system. Prior to SSM Health,
he was the System Corporate Chief Medical Officer at City of Hope
(Formerly Cancer Treatment Centers of America). He holds a B.S. in
biology from Loyola College and a Doctor of Medicine degree from
the University of Maryland, Baltimore.
“We are delighted for George to join Myriad to lead our oncology
commercial and clinical strategy as we continue to expand our
oncology portfolio,” said Mark Verratti, Chief Commercial Officer,
Myriad Genetics. “His extensive healthcare leadership experience
and successful track record will be key to accelerating our
strategy with health systems and large oncology practices to be the
precision medicine partner of choice.”
“Myriad Genetics has a long history of significant contributions
to oncology. I am thrilled to be working with such transformative
executive and scientific leaders to present industry-pioneering
options to millions of patients, their families, and providers who
care for them,” said Dr. Daneker.
About Myriad Genetics Myriad Genetics is a
leading genetic testing and precision medicine company dedicated to
advancing health and well-being for all. Myriad develops and offers
genetic tests that help assess the risk of developing disease or
disease progression and guide treatment decisions across medical
specialties where genetic insights can significantly improve
patient care and lower healthcare costs. For more information,
visit www.myriad.com.
Safe Harbor Statement This press release
contains “forward-looking statements” within the meaning of the
Private Securities Litigation Reform Act of 1995, including that
Dr. Daneker will be instrumental in leading the continued
innovation, growth and development of the company’s oncology
portfolio, including the company’s planned product expansions into
liquid biopsy and MRD testing. These “forward-looking statements”
are management’s expectations of future events as of the date
hereof and are subject to known and unknown risks and uncertainties
that could cause actual results, conditions, and events to differ
materially and adversely from those anticipated. Such factors
include those risks described in the company’s filings with the
U.S. Securities and Exchange Commission, including the company’s
Annual Report on Form 10-K filed on March 1, 2023, as well as any
updates to those risk factors filed from time to time in the
company’s Quarterly Reports on Form 10-Q or Current Reports on Form
8-K. Myriad is not under any obligation, and it expressly disclaims
any obligation, to update or alter any forward-looking statements,
whether as a result of new information, future events or otherwise
except as required by law.
Investor ContactMatt Scalo(801)
584-3532IR@myriad.com
Media ContactGlenn Farrell(385)
318-3718PR@myriad.com
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From Apr 2024 to May 2024
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From May 2023 to May 2024